Drug delivery from ocular implants

Expert Opinion on Drug Delivery

Volumn 3, Issue 2, 2006, Pages 261-273

  Yasukawa, Tsutomu ^a   Ogura, Yuichiro ^a   Kimura, Hideya ^b   Sakurai, Eiji ^a   Tabata, Yasuhiko ^c  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^b Nagata Eye Clinic   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Controlled release; Drug delivery system; Implants; Sustained release; Vitreoretinal diseases

Indexed keywords

ALBUMIN; ALGINIC ACID; ALTEPLASE; ANTIFUNGAL AGENT; ANTIMETABOLITE; ANTIVIRUS AGENT; BETAMETHASONE SODIUM PHOSPHATE; CHITOSAN; COLLAGEN; DEXAMETHASONE; DOXORUBICIN; ETHYLENE VINYL ACETATE COPOLYMER; EYE DROPS; FLUCONAZOLE; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FLUOROURIDINE; FOSCARNET; GANCICLOVIR; GELATIN; HYDROXYPROLINE; HYDROXYPROPYLCELLULOSE; IMMUNOSUPPRESSIVE AGENT; PILOCARPINE; POLY(ORTHO ESTER); POLYANHYDRIDE; POLYMER; PROSERT; STEROID; TRIAMCINOLONE; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIODEGRADABLE IMPLANT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INTRAOCULAR HYPERTENSION; KIDNEY DYSFUNCTION; NONHUMAN; OPTIC DISK; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA ROD; RETINA VEIN OCCLUSION; RETINITIS; SUSTAINED DRUG RELEASE; VITREORETINOPATHY;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE DISEASES; HUMANS; POLYMERS;

EID: 33644776490     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.3.2.261     Document Type: Article

References (54)

1. AMBATI J, ADAMIS AP: Transscleral drug delivery to the retina and choroid. Prog. Retin. Eye Res. (2002) 21(2):145-151.
2. GEROSKI DH, EDELHAUSER HF: Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. (2001) 52(1):37-48.
3. MAURICE DM, MISHIMA S: Ocular pharmacokinetics. In: Pharmacology of the Eye. ML Sears (Ed.), Springer-Verlag, New York, NY, USA (1984):19-116.
4. LANG JC: Ocular drug delivery conventional ocular formulations. Adv. Drug Deliv. Rev. (1995) 16(1):39-43.
5. BOCHOT A, COUVREUR P, FATTAL E: Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res. (2000) 19(2):131-147.
6. CANTRILL WH, HENRY K, MELROE NH, KNOBLOCH WH, RAMSEY RC, BALFOUR HH: Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology (1989) 96(3):367-374.
7. COCHEREAU-MASSIN I, LEHOANG P, LAUTIER-FRAU M, ZAZUN L, ROBINET M: Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology (1991) 98(9):1348-1355.
8. HEINEMANN MH: Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch. Ophthalmol. (1989) 107(12):1767-1772.
9. USSERY FM III, GIBSON SR, CONKLIN RH, PILOT DF, STOOL EW, CONKLIN AJ: Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology (1988) 95(5):640-648.
10. HENDERLY DE, FREEMAN WR, CAUSEY DM, RAO NA: Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology (1987) 94(4):425-434.
11. HOLLAND GN, SAKAMOTO MJ, HARDY D, SIDIKARO Y, KREIGER AE, FRENKEL LM: The UCLA CMV Retinopathy Study Group. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxyl-1-(hydroxy-methyl)ethoxymethyl] guanine. Arch. Ophthalmol. (1986) 104(12):1794-1800.
12. JABS DA, NEWMAN C, DE BUSTROS S, POLK, BF: Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology (1987) 94(7):824-830.
13. PEYMAN GA, KHOOBEHI B, TAWAKOL M et al.: Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina (1987) 7(4):227-229.
14. MORITERA T, OGURA Y, HONDA Y, WADA R, HYON SH, IKADA Y: Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Vis. Sci. (1991) 32(6):1785-1790.
15. SANBORN GE, ANAND R, TORTI RE et al.: Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Arch. Ophthalmol. (1992) 110(2):188-195.
16. HASHIZOE M, OGURA Y, KIMURA H et al.: Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch. Ophthalmol. (1994) 112(10):1380-1384.
17. KIMURA H, OGURA Y, HASHIZOE M, NISHIWAKI H, HONDA Y, IKADA Y: A new vitreal drug delivery system using an implantable biodegradable polymer device. Invest. Ophthalmol. Vis. Sci. (1994) 35(6):2815-2819.
18. MUSCH DC, MARTIN DF, GORDON JF, DAVIS MD, KUPPERMANN BD: Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. Ganciclovir Implant Study Group. N. Engl. J. Med. (1997) 337(2):83-90.
19. JONAS JB, HAYLER JK, PANDA-JONAS S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br. J. Ophthalmol. (2000) 84(9):1064-1067.
20. LIM JI, WOLITZ RA, DOWLING AH, BLOOM HR, IRVINE AR, SCHWARTZ DM: Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. (1999) 127(3):288-293.
21. OKABE K, KIMURA H, OKABE J, KATO A, KUNOU N, OGURA Y: Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Vis. Sci. (2003) 44(6):2702-2707.
22. KATO A, KIMURA H, OKABE K, OKABE J, KUNOU N, OGURA Y: Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Vis. Sci. (2004) 45(1):238-244.
23. JAFFE GJ, BEN-NUN J, GUO H, DUNN JP, ASHTON P: Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology (2000) 107(11):2024-2033.
24. JAFFE GJ, PEARSON PA, ASHTON P: Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina (2000) 20(4):402-403.
25. JAFFE GJ, YANG CS, WANG XC, COUSINS SW, GALLEMORE RP, ASHTON P: Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology (1998) 105(1):46-56.
26. JAFFE GJ, MCCALLUM RM, BRANCHAUD B, SKALAK C, BUTUNER Z, ASHTON P: Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology (2005) 112(7):1192-1198.
27. YANG CS, KHAWLYJA, HAINSWORTH DP et al.: An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. (1998) 116(1):69-77.
28. KIMURA H, OGURA Y: Biodegradable polymers for ocular drug delivery. Ophthalmologica (2001) 215(3):143-155.
29. HERRERO-VANRELL R, REFOJO MF: Biodegradable microspheres for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. (2001) 52(1):5-16.
30. HORA MS, RANA RK, NUNBERG JH, TICE TR, GILLEY RM, HUDSON ME: Release of human serum albumin from poly(lactide-co-glycolide) microspheres. Pharm. Res. (1990) 7(11):1190-1194.
31. KUNOU N, OGURA Y, HASHIZOE M, HONDA Y, HYON SH, IKADA Y: Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release (1995) 37(1-2):143-150.
32. PITT CG, GRATZL MM, JEFFCOAT AR, ZWEIDINGER R, SCHINDLER A: Sustained drug delivery systems. II. Factors affecting release rates from poly(e-caprolactone) and related biodegradable polymers. J. Pharm. Sci. (1979) 68(12):1534-1538.
33. SANDERS LM, KENT JS, MCRAE GL, VICKERY BH, TICE TR, LEWIS DH: Controlled release of a luteinizing hormone-releasing hormone analogue from poly(D, L-lactide-co-glycolide) microspheres. J. Pharm. Sci. (1984) 73(9):1294-1297.
34. YASUKAWA T, KIMURA H, TABATA Y, OGURA Y: Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. (2001) 52(1):25-36.
35. OGAWA Y, OKADA H, YAMAMOTO M, SHIMAMOTO T: In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic)acids and in vivo degradation of these polymers. Chem. Pharm. Bull. (1988) 36(7):2576-2581.
36. KUNOU N, OGURA Y, YASUKAWA T et al.: Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release (2000) 68(2):263-271.
37. HASHIZOE M, OGURA Y, TAKANASHI T, KUNOU N, HONDA Y, IKADA Y: Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr. Eye Res. (1997) 16(7):633-639.
38. YASUKAWA T, KIMURA H, KUNOU N et al.: Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefes Arch. Clin. Exp. Ophthalmol. (2000) 238(2):186-190.
39. SAKURAI E, MATSUDA Y, OZEKI H, KUNOU N, NAKAJIMA K, OGURA Y: Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Vis. Sci. (2001) 42(9):2043-2048.
40. MIYAMOTO H, OGURA Y, HASHIZOE M, KUNOU N, HONDA Y, IKADA Y: Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. (1997) 16(7):930-935.
41. HASHIZOE M, OGURA Y, TAKANASHI T, KUNOU N, HONDA Y, IKADA Y: Biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr. Eye Res. (1995) 14(6):473-477.
42. RUBSAMEN PE, DAVIS PA, HERNANDEZ E, O'GRADY GE, COUSINS SW: Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. (1994) 112(3):407-413.
43. ZHOU T, LEWIS H, FOSTER RE, SCHWENDEMAN SP: Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release (1998) 55(2-3):281-295.
44. SAKURAI E, NOZAKI M, OKABE K, KUNOU N, KIMURA H, OGURA Y: Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Vis. Sci. (2003) 44(2):4845-4852.
45. MORITA Y, OHTORI A, KUMURA M, TOJO K: Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(D,L-lactic acid) implants. Biol. Pharm. Bull. (1998) 21(2):188-190.
46. OKABE J, KIMURA H, KUNOU N, OKABE K, KATO A, OGURA Y: Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. Invest. Ophthalmol. Vis. Sci. (2003) 44(2):740-744.
47. YASUKAWA T, KIMURA H, TABATA Y, MIYAMOTO H, HONDA Y, OGURA Y: Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefes Arch. Clin. Exp. Ophthalmol. (2002) 240(8):672-678.
48. EINMAHL S, PONSART S, BEJJANI RA et al.: Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J. Biomed. Mater. Res. A (2003) 67(1):44-53.
49. EINMAHL S, SAVOLDELLI M, D'HERMIES F, TABATABAY C, GURNY R, BEHAR-COHEN F: Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest. Ophthalmol. Vis. Sci. (2002) 43(5):1533-1539.
50. HERRERO-VANRELL R, RAMIREZ L, FERNANDEZ-CARBALLIDO A, REFOJO MF: Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. Pharm. Res. (2000) 17(10):1323-1328.
51. YASUKAWA T, OGURA Y, TABATA Y, KIMURA H, WIEDEMANN P, HONDA Y: Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. (2004) 23(3):253-281.
52. TABATA Y, IKADA Y: Protein release from gelatin matrices. Adv. Drug Deliv. Rev. (1998) 31(3):287-301.
53. TAIPALE J, KESKI-OJA J: Growth factors in the extracellular matrix. FASEB J. (1997) 11(1):1-59.
54. YANG CF, YASUKAWA T, KIMURA H et al.: Experimental corneal neovascularization by basic fibroblast growth factor incorporated into gelatin hydrogel. Ophthalmic Res. (2000) 32(1):19-24.